Adrenergic Stimulation of Regional Plasminogen Activator Release in Rabbits

Summary

The purpose of this study was to determine whether different regions of the rabbit vascular system show variations in the rate of plasminogen activator (PA) secretion. To start, we evaluated the time course, dose response and adrenergic specificity of PA release. Infusion of 1 µg/kg of epinephrine stimulated a 116 ± 60% (SD) increase in PA activity that peaked 30 to 60 s after epinephrine administration. Infusion of 1 µg/kg of norepinephrine, isoproterenol and phenylephrine had no effect on PA activity. Pretreatment with phentolamine, an alpha adrenergic antagonist, blocked the release of PA by epinephrine while pretreatment with the beta blocker propranolol had no effect. This suggests that PA release in the rabbit was mediated by some form of alpha receptor.

Significant arterio-venous differences in basal PA activity were found across the pulmonary and splanchnic vascular beds but not the lower extremity/pelvic bed. After stimulation with epinephrine, PA activity increased 46% across the splanchnic bed while no change was seen across the lower extremity/pelvic bed. We conclude that several vascular beds contribute to circulating PA activity in the rabbit, and that these beds secrete PA at different rates under both basal and stimulated conditions.

• REFERENCES

• 1 van Hinsberg VWM. Synthesis and secretion of plasminogen activators and plasminogen activator inhibitor by endothelial cells. In: Tissue-Type Plasminogen Activator (t-PA): Physiological and Clinical Aspects. Kluft C. (ed) CRC Press, Boca Raton: 1988. 2 03-20
• 2 Schmidt RF, Thews G. Human Physiology. Springer Verlag, Berlin: 1983
• 3 Gader AMA, Clarkson AR, Cash JD. The plasminogen activator and coagulation factor VIII responses to adrenaline, noradrenaline, iso-prenaline and salbutamol in man. Thromb Res 1973; 2: 09-16
• 4 Gader AMA, da Costa J, Cash JD. The effect of propranolol, alprenolol and practolol on the fibrinolytic and factor VIII responses to adrenaline and salbutamol in man. Thromb Res 1974; 4: 25-33
• 5 Jern C, Eriksson E, Tengborn L, Risberg B, Wadenvik H, Jern S. Changes in plasma coagulation and fibrinolysis in response to mental stress. Thromb Haemostas 1989; 62: 767-771
• 6 Fracasso JF, Rothschild AM. Alpha and beta adrenergic blocker-resistant release of fibrinolytic activity from rat venae cavae by epinephrine in vitro. Thromb Haemostas 1983; 63: 49
• 7 Probst A, Lill H, Strein K. Beta-adrenergic receptor mediated release of tissue plasminogen activator in anaesthetized dogs. Thromb Res 1988; 50: 09-17
• 8 Holemans R. Enhancement of fibrinolysis in the dog by injection of vasoactive drugs. Am J. Physiol 1965; 208: 511-520
• 9 Emeis JJ. Perfused rat hindlegs. A model to study plasminogen activator release. Thromb Res 1983; 30: 195-203
• 10 Markwardt F, Klöcking HP. Studies on the release of plasminogen activator. Thromb Res 1976; 8: 217-223
• 11 Chandler WL, Schmer G, Stratton JR. Optimum conditions for the stabilization and measurement of tissue plasminogen activator in human plasma. J Lab Clin Med 1989; 113: 362-371
• 12 Chandler WL, Trimble SL, Loo S-C, Mornin D. Effect of PAI-1 levels on the molar concentrations of active tissue plasminogen activator (t-PA) and t-PA/PAI-1 complex in plasma. Blood 1990; 76: 930-937
• 13 Murthy VS, Hwang TF, Wurm R, Zagar ME, Keith RA, Kau ST, Salama AI, Giles RE. Insurmountable beta receptor blockade by ICI 147,798 in rabbits. J Pharmacol Exp Therap 1989; 248: 249-255
• 14 Calvo JJ, de Dios I, Plaza MA, San Roman JI, Lopez MA. Alpha-adrenergic influences on exocrine pancreatic secretion in the rabbit. Arch Intern Physiol Biochim 1989; 97: 455-463
• 15 Vassalli J-D, Dayer JM, Wohlwend A, Belin D. Concomitant secretion of prourokinase and of a plasminogen activator specific inhibitor by cultured human monocytes-macrophages. J Exp Med 1984; 159: 1653-1668
• 16 Tissot JD, Schneider P, Hauert J, Ruegg M, Kruithoff EKO, Bachmann F. Isolation from human plasma of a plasminogen activator identical to urinary high molecular weight urokinase. J Clin Invest 1982; 70: 1320-1323
• 17 Cash JD, Woodfield DG, Allan AGE. Adrenergic mechanisms in the systemic plasminogen activator response to adrenaline in man. Br J Haematol 1970; 18: 487-494
• 18 Larsson PT, Wiman B, Olsson G, Angelin B, Hjemdahl P. Influence of metoprolol treatment on sympatho-adrenal activation of fibrinolysis. Thromb Haemostas 1990; 63: 482-487
• 19 Nieuwenhuizen W. Fibrinogen and its specific sites for modulation of t-PA induced fibrinolysis. In: Tissue-Type Plasminogen Activator (t-PA): Physiological and Clinical Aspects. Kluft C. (ed) CRC Press, Boca Raton,: 1988. 1 171-187
• 20 Gurewich V, Panneli R, Louie S, Kelley P, Suddith RL, Greenlee R. Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). J Clin Invest 1984; 73: 1731-1739
• 21 Matsuo O, Rijken DC, Collen D. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro. Thromb Haemostas 1981; 45: 225-229
• 22 Vassalli J-D, Belin D. Amiloride selectively inhibits the urokinase-type plasminogen activator. FEBS 1987; 214: 187-191
• 23 Hassett MA, Krishnamurti C, Barr CF, Alving BM. The rabbit as a model for studies of fibrinolysis. Thromb Res 1986; 43: 313-323